AI in Bioprocessing

There is no single dominant platform or industry-standard software vendor in the market. Instead, teams pull from a highly fragmented landscape of tools. Commercial vendors account for roughly a fifth of the primary software used, with the remainder of the industry drawing from open-source libraries, academic software, and joint development partnerships.

Most companies choose to leverage external software or existing open-source frameworks rather than developing proprietary tools internally. Only a small minority of organizations build their AI applications in-house, a figure that matches the number of companies using no AI tools at all. Developing custom machine learning models internally requires substantial resources, making external sourcing the preferred approach.

Offline development applications deliver the most predictable and reliable results. Nearly half of process professionals report that offline workflows see the greatest benefit, specifically within Design of Experiments (DoE), process optimization, and predicting process performance. In contrast, online real-time optimization and automation systems carry high uncertainty, with many teams still unsure where real-time tools provide concrete advantages.

The primary bottlenecks to successful deployment are internal readiness and strategic focus, rather than the technology itself. Implementation typically stalls due to a lack of internal expertise to run the software and poor data availability caused by disconnected or unorganized data systems. Furthermore, over half of deployment efforts are slowed down simply because leadership mandates AI adoption without actively allocating dedicated project time or clear performance metrics to the engineering team.

No. The industry strongly favors upskilling existing engineering teams over recruiting external machine learning specialists. Because process development requires deep biological domain knowledge, it is far more practical to train existing process engineers on basic AI software than it is to teach complex bioprocessing workflows to generalist data scientists. The most effective path to integration relies on training current employees while focusing heavily on better data management.

Standalone Large Language Models (LLMs) generate responses based on language patterns rather than physical laws, making them fundamentally unsuited for complex, multi-step calculations like dynamic feeding profiles. To deploy them safely, GenAI should never act as an independent decision-maker. Instead, it must serve as a conversational interface layered over validated mathematical and hybrid process models. This allows engineers to use natural language to query data and set up simulations, while the underlying physical model acts as a safeguard to verify that all recommendations fit within actual equipment and biological limits.

To ensure a successful deployment, process development teams should evaluate software vendors against four practical checkpoints:

Hybrid Architecture: Avoid purely data-driven "black box" machine learning models, which require massive datasets and can output physically impossible predictions. Prioritize hybrid tools that constrain predictions within mechanistic physical laws (such as mass and energy balances).

Data Ingestion and Contextualization: Assess how easily the tool unifies and structures disconnected data from different runs, bioreactors, and historical files. A tool that requires manual data cleaning or brittle custom data pipelines will stall on the ground.

Operational Accessibility: Ensure the software is designed for process engineers and scientists rather than data scientists. The interface must allow your existing team to query, run simulations, and analyze results without needing to write custom code.

Compliance and Validation Readiness: For clinical or commercial workflows, select platforms built with GxP compliance, data integrity standards, and audit trail capabilities (such as 21 CFR Part 11) to avoid validation bottlenecks down the road.